Aurobindo Pharma Limited

Shankar Reddy Budidet

Sivakumaran Meenakshisunderam

Subba Reddy Danda

Jagan Mohan Reddy Sanapureddy

Somappa Somannavar Yallappa

Ramesh Dandala

Gangadhara Bhima Shankar Nangi

Senthil Kumar Natarajan

Kishore Karumanchi

Islam Aminul

Brajesh Kumar Sinha

Gowrisankar Rao Kaki

Srinivasa Rao Yatcherla

Srinivasachary Katuroju

Nageshwar Dussa

Bhima Shankar Gangadhara

Raveendra Reddy Chinta

Mahendar Reddy Nayini

Somappa Somannavar Yallapa

The present invention provides a process for the preparation of crystalline anhydrous compound of Formula (X), Further, the present invention relates to the use of compound of Formula (X) preparation of Raltegravir (I) or its pharmaceutically acceptable salt thereof. 

Process for the preparation of raltegravir

The present invention provides (R)-3-Amino-1-butanol (D)-tartarate (IIb); process for its preparation and its conversion to Dolutegravir. The present invention also provides an improved process for the preparation of Dolutegravir (I) or pharmaceutically acceptable salts wherein compound (XVI) is reacted with an optically active acid addition salt of (R)-3-amino-1-butanol (IIa). 

Process for the preparation of Dolutegravir

The present invention relates to a process for the preparation of pure Valsartan (I) substantially free from impurities of formulae (Ia), (Ib), and (Ic), which comprises: (i) condensing 2-(4'-bromomethylphenyl)benzonitrile of formula (II) with L-valine methyl ester hydrochloride of formula (V) in the presence of a base in a solvent to produce N-[(2&#x2032;-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester of formula (VI); (ii) treating the compound VI of step (i) with acid followed by treating with base to produce pure compound VI substantially free from dimeric impurity of formula (Via); (iii) reacting the pure compound of formula (VI) with n-valeryl chloride in the presence of a base to produce pure N-valeryl-N-[(2&#x2032;-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester (VII) substantially free from alkene impurity of formula (Vila); (iv) reacting the compound of formula (VII) with trialkyltin chloride and a metal azide in a solvent at a reflux temperature to produce N-(1-oxopentyl)-N-[[2&#x2032;-(2-tributyltintetrazol-5-yl)-(1,1&#x2032;-biphenyl)-4-yl]methyl]-(L)-valine methyl ester of formula (VHIb) free from thermal degradation impurity (Villa); (v) hydrolyzing the compound of formula (VHIb) in the presence of alkaline conditions to produce Valsartan (I).

Process for the preparation of valsartan

An improved process for the preparation of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole of Formula I, (I) with high enantiomeric excess from racemic mixture. 

Process for preparing an optically active proton pump inhibitor

Growing community of inventors

Hyderabad Telangana, India

Shankar Reddy Budidet